Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma (LINES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02546544
Recruitment Status : Completed
First Posted : September 11, 2015
Results First Posted : June 3, 2019
Last Update Posted : June 3, 2019
Sponsor:
Collaborators:
European Organisation for Research and Treatment of Cancer - EORTC
European Commission
Astellas Pharma Inc
Oxford University Hospitals NHS Trust
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
This is an international, multi-centre, single arm Bayesian designed phase 2 study to identify and determine the safety and activity of anti-IGF-1/IR inhibition in patients with relapsed and/or refractory ESFT. Approximately 40 patients will be recruited from 5-7 European centres. Each patient will be treated with single agent linsitinib, 600 mg orally once a day for days 1-3, 8-10 and 15-17 on a 21 day cycle until disease progression or undue toxicity.

Condition or disease Intervention/treatment Phase
Relapsed Ewing Sarcoma Refractory Ewing Sarcoma Drug: Linsitinib Phase 2

Detailed Description:

An important development in ES has been the identification of IGF-1R pathway dependency. The reasons for the remarkable single agent efficacy observed in a small subset of patients remains unknown, as is the relative lack of efficacy in the majority of patients. There may be heterogeneity in response due to partial signal pathway inhibition at the tumour level, inherent resistance in ES cells or the presence of alternative pathway activation through IR-A receptor signalling.

Here we aim to establish pharmacodynamic responses in ES tumours using functional imaging 18FDG-PET-CT and repeat post treatment biopsy for biomarker responses, toxicity and clinical outcome to the dual anti-IGF-1R/IR kinase blocking single agent linsitinib.

This is a single arm phase 2 study utilising adaptive Bayesian analysis. Approximately 40 patients will be recruited the national bone sarcoma centre in 5 EU countries over 18 months.

Eligible patients will take 4x 150 mg tablets once a day, days 1-3 of the week followed by 4 days off - repeated for 3 weeks = one treatment cycle. Patients can remain on treatment for as long as they gain clinical benefit.

The primary objectives are to determine the effect of linsitinib on the patient's tumours in terms of changes in biomarker and PET scans and to establish the safety of the trial drug (linsitinib) in Ewing sarcoma at the dose and treatment schedule being used in the trial.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma
Study Start Date : March 2014
Actual Primary Completion Date : July 15, 2016
Actual Study Completion Date : July 15, 2016


Arm Intervention/treatment
Linsitinib
Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
Drug: Linsitinib
Other Names:
  • OSI-906
  • ASP7487




Primary Outcome Measures :
  1. Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 [ Time Frame: Pre- and Post- dose responses following 1 cycle (21 days) of treatment ]

    Metabolic response measured by PERCIST v1.0 using SULpeak. This methodology used SULpeak to measure change in glucose uptake in the tumour.

    Complete Metabolic Response - Complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels.

    Partial Metabolic Response - Reduction of minimum of 30% in target measurable tumour 18F-FDG SULpeak. Absolute drop in SUL must be at least 0.8 SUL units, as well. No new lesions.

    Positive Metabolic Response - Participants having either "Complete Metabolic Response" or "Partial Metabolic Response".

    Stable Metabolic Disease - Not CMR, PMR or PMD. Progressive metabolic disease - Increase of more than 30% in 18F-FDG SUL peak. OR: Visible increase in extent of 18F-FDG tumour uptake (75% in TLG volume with no decline in SUL. OR: New 18F-FDG-avid lesions that are typical of cancer and not related to treatment effect or infection.


  2. Number of Participants With a Toxic Event [ Time Frame: Following 6 cycles of treatment (up to 6 months) ]
    A patient is defined as having a toxic event if they experienced at least one grade 3 adverse event (CTCAE v4.0 grade)


Secondary Outcome Measures :
  1. Clinical Outcome (PFS, DSS) [ Time Frame: Duration of study (up to 18 months) ]

    To determine the clinical outcome through assessment of

    • Progression free survival; where length of survival is defined in whole days as the time from entry into the study until Ewing sarcoma progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
    • Disease specific survival; where length of survival is defined in whole days as the time from entry into the study until death from Ewing sarcoma.

  2. Pharmacokinetics Assays of Following Linsitinib Treatment (Plasma Concentrations of Linsitinib) [ Time Frame: Cycle 1 days 1,15,17, Cycle 2 day 3, Cycle 3 days 1 and 3, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1 and End of Treatment.0 ]

    Plasma concentrations of linsitinib (ng/ml).

    Samples were taken 3 hours post-dose at Cycle 1 days 1,15,17, Cycle 2 day 3, Cycle 3 days 1 and 3, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, and End of Treatment (this could occur at anytime during the 6 cycles).


  3. Number of Participants With a Radiological Response as Evaluated by RECIST v1.1 [ Time Frame: Measured cycle 1 day 15, cycle 3 and cycle 6 ]

    Radiological response measured using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)

    Per RECIST for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), >20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable disease (SD), Not CR, PR or PD.


  4. Number of Participants With a Metabolic Response as Evaluated by EORTC 1.0 [ Time Frame: Measured cycle 1 day 15 ]

    Metabolic response measured by PERCIST v1.0 using SULpeak. This methodology used SULpeak to measure change in glucose uptake in the tumour.

    Complete Metabolic Response - Complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels.

    Partial Metabolic Response - Reduction of minimum of 30% in target measurable tumour 18F-FDG SULpeak. Absolute drop in SUL must be at least 0.8 SUL units, as well. No new lesions.

    Positive Metabolic Response - Participants having either "Complete Metabolic Response" or "Partial Metabolic Response".

    Stable Metabolic Disease - Not CMR, PMR or PMD. Progressive metabolic disease - Increase of more than 30% in 18F-FDG SUL peak. OR: Visible increase in extent of 18F-FDG tumour uptake (75% in TLG volume with no decline in SUL. OR: New 18F-FDG-avid lesions that are typical of cancer and not related to treatment effect or infection.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological or cytological confirmed original (no new biopsy required) diagnosis of Ewing sarcoma, preferably with EWSR in situ hybridisation break apart probe.
  • First, second or any relapse or refractory disease to conventional treatment
  • Current disease state for which there either is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
  • Has recovered from prior chemotherapy-related toxicity to ≤ grade 2
  • Male or female, Age ≥ 18 and ≤70 years
  • Life expectancy of at least 4 months
  • WHO performance score of 0-2
  • Must be able to take oral medication
  • Is willing and able to comply with the protocol for the duration of the study, and scheduled visits and examinations, including biopsies and PET-CT scans
  • Written (signed and dated) informed consent
  • Tumour at biopsy accessible site; in the case of lung metastases, accessible with VATS procedure
  • Tumour progression documented with imaging in the 6 months prior to study entry
  • At least one measurable lesion on CT scan performed in past 14 days of minimum size 1 cm and 18FDG uptake positive
  • Cardiac Ejection Fraction (Echocardiogram) ≥45%
  • Fasting glucose ≤ 150 mg/dL (8.3 mmol/L) with no history of diabetes. Concurrent use of non-insulinotropic anti-hyperglycaemic therapy for diabetes is permitted if the dose has been stable for ≥ 4 weeks at the time of enrolment
  • 16. Haematological and biochemical indices within the specified ranges as below:

    • Haemoglobin (Hb) ≥9 g/dL (Previous transfusion is allowed)
    • Absolute neutrophil count (ANC) ≥1.0 x 109/L without growth factor support
    • Platelet count > 80.x 109/L (Previous transfusion is allowed)
    • Direct Bilirubin <1.5 times the upper limit of normal (ULN)
    • Serum alanine aminotransferase (ALT) <2.5 x ULN for age and ≤ 5 x ULN if liver metastasis
    • Aspartate aminotransferase (AST) <2.5 x ULN for age
    • Alkaline phosphatase <2.5 x ULN for age
    • CPK <2.5 x ULN for age
    • Serum creatinine ≤1.5 x ULN for age
    • Potassium, magnesium and calcium within normal limits (supplementation and re-testing is permitted)

Exclusion Criteria:

  • Females: Pregnant or breast-feeding, or of childbearing potential unless effective methods of contraception are used. Males: Unless effective methods of contraception are used.
  • Significant active cardiac disease including: History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; clinically significant ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea).
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded; uncontrolled high blood pressure (no greater than 2 SD above the mean for age for SBP and DBP), unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias
  • Mean QTcF interval ≥ 450 msec based on analysis of screening visit and pre-dose ECGs.
  • 5. Use of drugs that have a known risk of causing Torsades de Pointes (TdP) within 14 days prior to registration
  • Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine within 7 days prior to registration. Linsitinib is primarily metabolized by CYP1A2 and inhibitors/inducers of CYP1A2 could alter the pharmacokinetics of linsitinib. Other less potent CYP1A2 inhibitors/inducers are not excluded
  • Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results
  • Any other active malignancy, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions
  • History of cerebrovascular accident (CVA) within 6 months prior to entry that resulted in ongoing neurologic instability
  • Patients with symptomatic brain metastases. Patients with previously diagnosed brain metastases are eligible if they have completed their CNS treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks, and are neurologically stable
  • Major surgery within 4 weeks prior to study treatment
  • Prior anti- IGF-1R treatment
  • Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment
  • Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02546544


Locations
Layout table for location information
France
Universitè Lyon 1 Claude Bernard
Lyon, France
Germany
Pediatric Hematology and Oncology, University Hospital Münster
Münster, Germany, 48149
Italy
Istituti Ortopedici Rizzoli
Bologna, Italy, 40136
Netherlands
Department of Clinical Oncology, Leiden University Medical Center
Leiden, Postzone K1-P, Netherlands, P.O. Box 9600
United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom, OX3 7LE
Sponsors and Collaborators
University of Oxford
European Organisation for Research and Treatment of Cancer - EORTC
European Commission
Astellas Pharma Inc
Oxford University Hospitals NHS Trust
Investigators
Layout table for investigator information
Principal Investigator: Andrew B Hassan, BMBCh FRCP University of Oxford

Additional Information:
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT02546544     History of Changes
Other Study ID Numbers: OCTO_038
2012-000616-28 ( EudraCT Number )
First Posted: September 11, 2015    Key Record Dates
Results First Posted: June 3, 2019
Last Update Posted: June 3, 2019
Last Verified: October 2017

Keywords provided by University of Oxford:
Linsitinib
anti-IGF-1R/IR
Ewing Sarcoma
dual IGF-1R/IR inhibition
Relapsed Ewing Sarcoma
Refractory Ewing Sarcoma
Metastatic Ewing Sarcoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue